Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2006-08-22
2006-08-22
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C424S196110, C435S005000, C435S007100, C435S183000, C435S188000, C435S015000, C435S193000
Reexamination Certificate
active
07094401
ABSTRACT:
The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so as to inhibit hepatitis C virus replication. The present invention also provides a method for determining whether a compound can treat or prevent hepatitis C virus infection in a subject, wherein the compound treats or prevents hepatitis C virus infection by specifically inhibiting the binding of HCV core protein and said agent so as to suppress hepatitis C virus replication. The present invention further provides a composition for inhibiting cell growth, comprises a HCV core protein or a variant thereof, wherein said HCV core protein or its variant inhibit cancer cell growth by inhibiting the cellular DEAD box proteins.
REFERENCES:
Owsianka and Patel, Virology 257, 330-340 (1999), May 10, 1999.
Alter, M.J. (1997) “Epidemiology of Hepatitis C”Hepatology,26:625-655 (Exhibit 2).
Chien, C., et al. (1991) “The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest”Proc. Natl. Acad. Sci. U.S.A.,88:9578-9582 (Exhibit 3).
Choo, Q.-L., et al. (1989) “Isolation of a cDNA clone derived from blood-borne nonA, nonB viral hepatitis genome”Science,244:359-362 (Exhibit 4).
Choo, Q.-L., et al. (1991) “Genetic organization and diversity of the hepatitis C virus”Proc. Natl. Acad. Sci. U.S.A.,88:2451-2455 (Exhibit 5).
Chuang, R.-Y., et al. (1997) “Requirement of the DEAD-box protein Dedlp for messenger RNA translation”Science,275:1468-1471 (Exhibit 6).
Fields, S., and Song, O. (1989) “A novel genetic system to detect protein—protein interactions”Nature,340:245-246 (Exhibit 7).
Fukushi, S., et al. (1997) “The sequence element of the internal to ribosome entry site and a 25-kilodalton cellular protein contribute efficient internal initiation of translation of hepatitis C virus RNA”J. Virol.,71:1662-1666 (Exhibit 8).
Gee, S. L., and Conboy, J. G. (1994) “Mouse erythroid cells express multiple putative RNA helicase genes exhibiting high sequence conservation form yeast to mammals”Gene,140:171-177 (Exhibit 9).
Hsieh, T.-Y. (1998) “Hepatitis C virus core protein intgeracts with hetrogeneous nuclear ribonucleprotein K”J. Biol. Chem.,271, 17651-17659 (Exhibit 10).
Kato, N., et al. (1990) “Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis”Proc. Natl. Acad. Sci. U.S.A.,87:9524-9528 (Exhibit 11).
Kim, J. L., et al. (1998) “Hepatitis C virus NS3 RNA helicase domian with a bound oligonucleotide : the crystal structure provides insights into the mode of unwinding”Structure,6:89-100 (Exhibit 12).
Kim, D. W., et al. (1994) “Trans-suppression of gene expression by hepatitis C viral core protein”Jpn. J. Med. Sci. Biol.,47:211-220 (Exhibit 13).
Kuo, G., et al. (1989) “An assay for circulating antibodies to a major etiological virus of human non-A, non-B hepatitis”Science,244:359-363 (Exhibit 14).
Lanford, R. E., et al. (1993) “Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells”Virology,197:225-235 (Exhibit 15).
Leroy, P., et al. (1989) “The protein encoded by a murine male germ cell-specific transcript is a putative ATP-dependent RNA helicase”Cell,57:549-559 (Exhibit 16).
Liang, T. J. (1998) “Combinaton therapy for hepatitis C Infection” N. Eng. J. Med., 339; 1549-1550 (Exhibit 17).
Mamiya,N., et al. (1997) “Epidemiology, prevention, clinical features and therapy of hepatitus B, C, and G” Current Opinion in Infectious Diseases., 10:390-397 (Exhibit 18).
Matsumoto, M., et al. (1996) “Homotypic interactions and multimerization of the hepatitis C virus core protein”Virology.,218:43-51 (Exhibit 19).
Matsumoto, M., et al. (1997) “Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor”J. Virol.71:1301-1309 (Exhibit 20).
Moradpour, D., Kary, P., rice, C. M., and Blum, H.E. (1998) “Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins”Hepatology,28:192-201 (Exhibit 21).
National Institutes of Health Consensus Development Conference Panel Statement (1997) “Management of Hepatitis C”Hepatology,26:2S-10S (Exhibit 22).
Okamoto, H., et al. (1991) “Nucleotide sequence of the genomic RNA hepatitis C virus isolated from a human carrier: comparison with reported isolates from conserved and divergent regions”J. Gen. Virol.,72:2697-6704 (Exhibit 23).
Ray, R. B., et al. (1996) “Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype”J. Virol.,70:4438-4443 (Exhibit 24).
Ray, R. B., et al. (1997) “Transcriptional repression of p53 promoter by hepatitis C virus core protein”J. Biol. Chem.,272:10983-10986 (Exhibit 25).
Reynolds, J. E., et al. (1995) “Unique features of internal initiation of hepatitis C virus RNA translation”EMBO J.,14:6010-6020 (Exhibit 26).
Rozen, F., et al. (1990) “Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F”Mol. Cell Biol.10:1134-1144 (Exhibit 27).
Selby, M. J., et al. (1993) “Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome”J. Gen. Virol.,74:1103-1113 (Exhibit 28).
Suzuki, R., et al. “Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted”J. Gen. Virol.,76:53-61 (Exhibit 29).
Takamizawa, A., et al. (1991) “Structure and organization of the hepatitis C genome isolated from human carriers”J. Viol.,65:1105-1113 (Exhibit 30).
Yao, N., et al. (1997) “Structure of the hepatitis C virus RNA helicase domain”Nat. Struct. Biol.,4:63-467 (Exhibit 31).
Ye, Q., and Worman, H. J. (1996) “Interaction between an integral protein of the nuclear envelope inner membrane and human chromodomain proteins homologous toDrosophilaHP1”J. Biol. Chem.,271:14653-14656 (Exhibit 32).
Zhu, N., et al. (1998) “Hepatitis C virus core protein binds to cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis”J. Virol.72:3691-3697 (Exhibit 33).
Mamiya Naoto
Worman Howard J.
Cooper & Dunham LLP
Scheiner Laurie
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
HCV core protein binding agents for treatment of hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HCV core protein binding agents for treatment of hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV core protein binding agents for treatment of hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636167